Halberd Corporation CEO Update Letter – October, 2020
Greetings From The CEO And Staff At Halberd Corporation! (OTC-PINK: HALB) This initial CEO Letter reflects a summary of major accomplishments since I began my tenure at Halberd Corporation. Going forward, I intend to provide update letters to our shareholders and the public on a quarterly basis. A LOOK BACK Since I began at Halberd back in May, I have been working on assembling a talented team of technical and business leaders (who, like me, ...
Halberd COVID-19 Preventative Nasal Spray Provisional Patent Application Filed
Jackson Center, PA, October 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced they have obtained world-wide license to a provisional patent application covering a nasal spray to be used as a prevention measure against coronavirus. The provisional patent, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” was filed recently with the U.S. Patent and Trademark Office by its inventor, Mitchell S. Felder, MD. The nasal spray is intended to be used as a ...
Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity
Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2). Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells. ACE2 (3) is a membrane protein expressed in many organs such as nasal and lung epithelial cells. Traditionally, ACE 2 has a key role in the blood pressure regulatory ...
Arizona State University/Halberd Corp. Covid-19 R&D Program Rapid Diagnostic Test / Treatment
Jackson Center, PA, September 24, 2020 – Halberd Corporation (OTC PINK: "HALB") clarifies next steps in their unique research with Arizona State University. Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious -- the spike antigen. ASU investigators have projected the production of the coronavirus spike antigen within the next two weeks. The next steps for the ASU/Halberd program involve identification of an antibody conjugate which ...
Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!
Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will immediately commence the identification of suitable antibodies. Dr. Chen expects to have proprietary antibodies within the next two weeks. Patent ...
Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program
Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent antibody-antigen complex, for the rapid identification of a Covid-19 sample. In an earlier press release, we enumerated the initial phase ...